In a 60-year-old patient with epilepsy on valproic acid (Depakote) and levetiracetam presenting for a follow-up visit, what history should be obtained and what laboratory/tests should be ordered?

Follow-Up Management for 60-Year-Old on Depakote and Levetiracetam

For a 60-year-old epilepsy patient on valproic acid (Depakote) and levetiracetam, you must obtain a detailed seizure history, assess medication adherence and adverse effects, and order liver function tests, complete blood count with platelets, and valproic acid serum level.

History to Obtain

Seizure Control Assessment

• Exact date and description of last seizure (not just "recent" - document the specific day and time)
• Seizure frequency pattern over the past 3-6 months compared to baseline
• Any change in seizure type or duration - worsening seizure control often indicates disease progression or medication issues
• Timing of seizures relative to medication doses (breakthrough seizures may indicate subtherapeutic levels)

Medication-Specific History

For Valproic Acid (Depakote):

• Hepatotoxicity symptoms: malaise, weakness, lethargy, facial edema, anorexia, vomiting 1
• Hematologic effects: easy bruising, bleeding gums, petechiae (thrombocytopenia risk increases at levels ≥110 mcg/mL in females, ≥135 mcg/mL in males) 1
• Weight gain and tremor (common long-term effects occurring in 20% of patients) 2
• Hair loss (alopecia)
• Menstrual irregularities in women

For Levetiracetam:

• Psychiatric symptoms: aggression, agitation, anger, anxiety, apathy, depression, hostility, irritability 3
• Behavioral changes or psychotic symptoms (rare but serious)
• Somnolence and dizziness affecting daily function 3

Adherence and Dosing

• Exact current doses of both medications and timing
• Missed doses in the past month (even 1-2 missed doses can trigger breakthrough seizures)
• Any self-adjustment of doses
• Drug interactions: specifically ask about new medications, over-the-counter drugs, or supplements

Functional Impact

• Driving status - document last seizure date relative to state driving regulations
• Employment or education - any seizure-related incidents or limitations
• Activities of daily living - cooking, bathing, heights (safety assessment)
• Quality of life - social isolation, depression, cognitive complaints

Red Flags Requiring Urgent Evaluation

• New neurological symptoms: headache, focal weakness, vision changes (may indicate tumor progression or stroke)
• Cognitive decline or personality changes
• Signs of status epilepticus or clustering seizures

Laboratory Tests and Monitoring

Essential Tests

1. Liver Function Tests (LFTs) 1

• AST, ALT, alkaline phosphatase, total bilirubin
• Critical for valproic acid monitoring - hepatotoxicity risk is highest in first 6 months but requires ongoing surveillance
• Obtain prior to visit if not done in past 3-6 months
• More frequent monitoring if patient has risk factors: multiple anticonvulsants, history of liver disease, or concerning symptoms

2. Complete Blood Count with Platelets 1

• Valproic acid causes dose-dependent thrombocytopenia
• Check for leukopenia (3% risk with levetiracetam vs 0% placebo in trials) 3
• Baseline and periodic monitoring essential

3. Valproic Acid Serum Level 2

• Therapeutic range: 50-100 mcg/mL (some sources use 50-125 mcg/mL)
• Levels ≥110 mcg/mL (females) or ≥135 mcg/mL (males) significantly increase thrombocytopenia risk 1
• Obtain trough level (before morning dose)
• Useful for assessing adherence, drug interactions, and dose optimization

4. Levetiracetam Level (Optional)

• Not routinely required as levetiracetam has wide therapeutic window
• Consider if: poor seizure control, suspected non-adherence, or drug interactions with enzyme-inducing medications 4

Additional Tests Based on Clinical Context

If seizure control has worsened:

• Brain MRI to rule out structural changes, tumor progression, or stroke 5
• EEG if considering medication adjustment or to rule out non-convulsive status epilepticus 5

If hepatotoxicity suspected:

• Ammonia level
• Coagulation studies (PT/INR, aPTT)
• Comprehensive metabolic panel

If thrombocytopenia present:

• Peripheral blood smear
• Consider dose reduction or medication change if platelet count significantly low

Common Pitfalls to Avoid

1. Don't rely solely on biochemistry for hepatotoxicity - clinical symptoms (malaise, weakness, lethargy, vomiting) may precede laboratory abnormalities 1

2. Don't ignore psychiatric symptoms on levetiracetam - 37.6% of patients may require dose adjustment or psychiatric intervention, though only 3.5% require discontinuation 6

3. Don't assume stable epilepsy means no monitoring needed - both medications require ongoing surveillance for dose-dependent toxicity

4. Don't overlook drug interactions - enzyme-inducing medications significantly reduce valproic acid and levetiracetam levels 4

5. Don't forget to document driving eligibility - this has legal and safety implications

Monitoring Frequency

• First 6 months of valproic acid therapy: LFTs every 2-4 weeks, then monthly 1
• After 6 months: LFTs and CBC every 3-6 months for stable patients 2
• Valproic acid levels: every 6-12 months or when adjusting dose
• More frequent monitoring if: symptoms develop, dose changes, new medications added, or abnormal results